Physician profile
Earl Franklin
NPI 1184615486
$177.41
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $78.15 | 2019 | |
| Phadia US INC. | $19.72 | 2019 | |
| Vertical Pharmaceuticals, LLC | $18.59 | 2019 | |
| Pfizer INC. | $15.99 | 2019 | |
| Glaxosmithkline, LLC. | $12.82 | 2019 | |
| Neos Therapeutics, LP | $12.34 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.26 | 2019 | |
| Merck Sharp & Dohme LLC | $7.54 | 2019 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earl Franklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.